Hair Loss & DHT

The DHT Mechanism

Dihydrotestosterone, produced from testosterone by the enzyme 5-alpha-reductase, binds the androgen receptor with higher affinity than testosterone itself. In genetically susceptible hair follicles, this DHT-androgen receptor binding progressively shortens the growth phase of the hair cycle and shrinks the follicle over successive cycles, a process called miniaturization, eventually producing the thin, short vellus hairs characteristic of male pattern baldness rather than an actual loss of follicles.

Finasteride & Dutasteride

Finasteride and dutasteride are both FDA-approved 5-alpha-reductase inhibitors, but they differ in scope. Finasteride selectively inhibits the type 2 isoenzyme, dutasteride inhibits both type 1 and type 2, giving it a more complete reduction in DHT production and generally greater efficacy for hair regrowth.^[1] Both work by reducing the substrate available to bind the androgen receptor at the follicle, rather than blocking the receptor itself.

Side Effects & Post-Finasteride Syndrome

The most commonly reported adverse effects of both drugs are sexual, erectile dysfunction, decreased libido, and ejaculatory dysfunction, reported in roughly 3.4 to 15.8 percent of men across studies, along with gynecomastia in some cases, attributed to reduced DHT alongside a shunting of the now-unconverted testosterone toward aromatization into estradiol.^[2]

RU58841 & Pyrilutamide: The Topical Approach

Rather than reducing DHT production systemically, a separate class of compounds works by directly blocking DHT from binding the androgen receptor at the scalp, locally, without necessarily lowering DHT anywhere else in the body. RU58841 is a non-steroidal antiandrogen studied since the 1990s, an early controlled study using balding human scalp grafted onto nude mice found it significantly increased hair growth rate and initiated more hair growth cycles, and a separate primate study evaluated it as a topical anti-alopecia agent in bald stump-tailed macaques.^[5] It has never completed the full regulatory approval process and remains a research chemical rather than a prescribed medication, meaning the manufacturing and purity oversight applied to an approved drug does not apply to it.

Pyrilutamide, also known as KX-826, is a newer topical androgen receptor antagonist in active clinical development, described as a silent antagonist, meaning it binds the androgen receptor and blocks DHT without triggering any downstream transcriptional activity of its own. In preclinical binding studies it shows considerably higher receptor affinity than other topical antiandrogens tested to date. Because it is designed with very low transdermal absorption, the working hypothesis is that it should carry a lower risk of the systemic side effects seen with oral 5-alpha-reductase inhibitors, though this has not yet been confirmed with the same depth of long-term data that exists for finasteride and dutasteride.^[6]

Practical Takeaway

Androgenetic alopecia is mechanistically well understood, DHT binding the androgen receptor at genetically susceptible follicles, and the treatment landscape splits cleanly along how directly each option engages that mechanism. Finasteride and dutasteride reduce DHT production systemically and carry a well-documented, non-trivial sexual and, in rare cases, persistent side effect profile. RU58841 and pyrilutamide attempt to solve the same problem locally at the scalp, a genuinely promising approach mechanistically, but one still working with a comparatively thin long-term human safety record.

Learn Next

To go deeper here, the concepts worth studying next are the hair growth cycle itself, anagen, catagen, and telogen phases, and how miniaturization specifically shortens anagen, the difference between a "silent antagonist" and a partial agonist at the androgen receptor, minoxidil's entirely separate potassium-channel mechanism as a non-hormonal complement to antiandrogen treatment, and the general principle of local versus systemic drug delivery, since the same tradeoff appears throughout pharmacology whenever a target tissue is accessible from the outside.